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Highlights 
 A one-site immunometric assay using affinity microcolumns was developed and tested. 
 Alpha1-acid glycoprotein (AGP) was used a model protein biomarker for this work. 
 Several theoretical and practical factors were considered in creating this assay. 
 These factors included conditions used for incubation, the reagents, and the microcolumn. 
 The final method required only 1 μL serum and had a detection limit of 0.63 nM AGP. 
 The same approach can be easily modified for use with for other protein biomarkers.  
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Abstract 
A one-site immunometric assay based on affinity microcolumns was developed for the 
analysis of alpha1-acid glycoprotein (AGP) as a model protein biomarker.  In this assay, a 
sample containing AGP was incubated with an excess amount of a labeled binding agent, such as 
fluorescein-labeled anti-AGP antibodies or Fab fragments.  The excess binding agent was 
removed by passing this mixture through a microcolumn that contained an immobilized form of 
AGP, while the signal was measured for the binding agent-AGP complex in the non-retained 
fraction.  Theoretical and practical factors were both considered in selecting the concentration 
of labeled binding agent, the incubation time of this agent with the sample, and the application 
conditions for this mixture onto the microcolumn.  The effects of using various labeling 
methods and intact antibodies vs Fab fragments were also considered.  The final assay was 
performed with fluorescein-labeled anti-AGP antibodies and a 2.1 mm i.d. × 1.0 cm AGP 
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microcolumn operated at 0.30 mL min
-1
.  This method required only 1 μL of serum, had a 
detection limit of 0.63 nM AGP, and gave a potential throughput of 2 min per sample.  This 
assay was used to measure AGP in normal serum and serum from patients with systemic lupus 
erythematosus, giving good agreement with the literature and a reference method.  The same 
approach and guidelines can be used to create assays for other protein biomarkers by changing 
the labeled binding agent and immobilized protein within the microcolumn.  
Keywords: chromatographic immunoassay, one-site immunometric assay, alpha1-acid 
glycoprotein, affinity microcolumn, systemic lupus erythematosus 
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1 Introduction 
Immunoassays are analytical techniques that use antibodies or antibody-related agents for 
the analysis of a given target compound [1,2].  These techniques rely on the selective and strong 
binding between an antibody and its target to provide assays that can often be used directly, and 
with minimal pretreatment steps, with complex samples such as serum or plasma [2,3].  In these 
methods, a column is used that contains one component of an immunoassay, making it possible 
to combine the binding selectivity and strength of antibodies with the precision, ease of 
automation, and speed of modern liquid chromatography [2–8].  
A one-site immunometric assay is one format that can be used in a chromatographic 
immunoassay (see Figure 1) [9–17].  In this method, a sample or standard that contains the 
target analyte is combined and incubated with an excess amount of a labeled binding agent for 
the target (e.g., an intact antibody or Fab fragment).  The amount of non-bound labeled agent 
that remains after the incubation step is removed by passing this mixture through a column or 
support that contains an immobilized analog of the target.  A signal that is related to the amount 
of analyte in the original sample is then obtained by measuring the amount of labeled binding 
agent that elutes non-retained from the column or that is captured by this column [9–17]. 
One-site immunometric assays have been previously used with traditional-sized columns 
and a number of targets with small-to-intermediate sizes (i.e., molar mass < 18 kDa) 
[9-16,18-21].  Examples have included assays for targets such as digoxin [9,10], thyroxine 
[11,15], β-estradiol [12], α-(difluoromethyl)ornithine [13], 2,4-dichlorophenoxyacetic acid [14], 
D-phenylalanine [16], interleukin-10, and human methionyl granulocyte column stimulating 
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factor [9-18].  It has only recently been shown that the same method can be used for proteins, as 
has been demonstrated for human serum albumin (HSA, the major protein in serum; normal 
concentration, 39-53 g L
-1
; molar mass, 66.5 kDa) [19,20].   
One development that has made the extension of one-site immunometric assays to protein 
targets feasible has been the use of affinity microcolumns (i.e., columns that contain an 
immobilized binding agent and with a size in the low-to-mid microliter range) [19,21].  
Advantages to using microcolumns in applications such as chromatographic immunoassays 
include their need for only a small amount of an immobilized agent, their good capture 
efficiencies for an applied target or binding agent, and their ability to produce methods with 
analysis times on the order of only a few minutes [21].  This report will examine the 
development of a one-site immunometric assay that uses affinity microcolumns to measure a 
protein biomarker that occurs at a low-to-intermediate concentration in a biological system.  
This process will be illustrated by using alpha1-acid glycoprotein (AGP) as a model target.      
AGP is an acute phase glycoprotein that consists of a single chain of 183 amino acids 
[22].  The molar mass of AGP ranges from 41 to 43 kDa, with glycan chains making up around 
45% of this mass [22].  The normal serum concentration of AGP in humans is 0.5-1.0 g L
-1
 
(12-24 μM), or up to 100-fold lower that the concentration of HSA [20].  However, AGP levels 
in some diseases can be increased by up to 10-fold [22,23].  The analysis of AGP in serum and 
plasma has been previously done by using single radial immunodiffusion, which can take up to 
48 h to perform [24,25].  Fluorescent probes such as auramine O and quinaldine red have also 
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been used to measure AGP; however, these assays are susceptible to non-specific binding or 
matrix effects and require relatively large sample volumes (i.e., 100-200 µL) [26,27].  Acidic 
precipitation and reversed-phase liquid chromatography have been used to measure AGP in 
plasma, but this approach requires 30 min to perform [28].  Capillary electrophoresis (CE) with 
electrophoretic injection has also been employed to measure AGP in serum, giving a method 
with a total analysis time of around 1 h [29].  Thus, there is still a need for a technique that can 
measure AGP in serum or related samples in both a rapid and selective manner. 
This report will examine the development and use of a one-site immunometric assay that 
employs an affinity microcolumn with fluorescence detection for the analysis of AGP in serum.  
Several theoretical and practical factors will be examined and considered in the creation of this 
method. These factors will include the concentration of labeled binding agent that should be used, 
the incubation time needed for this binding agent with the analyte, and the application conditions 
for this mixture onto an affinity microcolumn.  The use of intact antibodies or Fab fragments 
will be considered, as well as various methods for labeling these binding agents.  The analytical 
performance of the final method will then be characterized.  This approach will be examined for 
use in the measurement of AGP in normal serum and serum from patients with systemic lupus 
erythematosus (SLE), a disease in which elevated serum levels of AGP may occur [22,29].  The 
results of this study should provide useful guidelines for the development and optimization of 
similar assays for other protein biomarkers or targets of biomedical interest. 
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2  Experimental Section 
2.1  Reagents and Materials 
The AGP (from pooled human plasma, ≥ 99% pure; product number G9885), 
polyethylene oxide (PEO; viscosity-average molar mass, 8000 kDa), Brij 35 (number-average 
molar mass, 1.198 kDa), Lucifer yellow CH (LyCH, dilithium salt), normal human serum (from 
human male AB plasma, USA origin, sterile filtered; product number H4522), oxalic dihydrazide, 
D-glucose, N,N-dimethylformamide (DMF) and Amicon Ultra-4 centrifugal filters (4 mL, 30 
kDa cutoff) were from Sigma-Aldrich (St Louis, MO, USA).  The Zeba spin desalting columns 
(0.5 mL volume, 7 kDa cutoff), immobilized papain (on agarose), cysteine HCl, and 
N-hydroxysuccinimide (NHS)-fluorescein (> 90%) were purchased from Thermo Fisher 
Scientific (Rockford, IL, USA).  Goat anti-AGP polyclonal antibodies (catalog no. GAGP-80A, 
affinity-purified) were obtained from Lee Biosolutions (Maryland Heights, MO, USA).  The 
SLE serum samples were de-identified and pre-existing samples from individuals known to have 
this disease, as provided by Johns Hopkins University School of Medicine (Baltimore, MD, 
USA); the use of such samples for this work was determined to be exempt from IRB review by 
the Johns Hopkins School of Medicine, according to the Code of Federal Regulations − 45 CFR 
46.101 b.  All aqueous solutions and samples were prepared using water obtained from a 
Milli-Q Advantage A10 purification system (EMD Millipore Corporation, Billerica, MA, USA) 
and were filtered through 0.20 μm GNWP nylon membranes from Millipore.  
2.2  Apparatus 
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The affinity microcolumns were packed using a HPLC slurry packer from ChromTech 
(Apple Valley, MN, USA).  A MiniCentrifuge (Fisher Scientific, Pittsburgh, PA, USA) was used 
at 6600 rpm and room temperature with Zepa spin desalting columns.  A 5702RH 
temperature-controlled centrifuge (Eppendorf, New York, NY, USA) was used at 4400 rpm and 
25ºC with the Amicon Ultra-4 centrifugal filters. 
The one-site immunometric assays were performed with a Jasco HPLC system (Tokyo, 
Japan) that contained two PU-2080 isocratic pumps, an AS-2057 autosampler, a CO-2067 
column oven, a UV-2075 UV absorbance detector and a FP-2020 fluorescence detector.  A two 
position/six port valve from IDEX Health & Science (Rohnert Park, CA, USA) was used to 
switch the flow between the two isocratic pumps for sample loading and elution.  Frontal 
analysis was performed with a modified setup (see Supplemental Material) of this HPLC system, 
which had one PU-2080 isocratic pump, a two position/six port valve with a 5.0 mL sample loop, 
a CO-2067 column oven, and a UV-2075 UV absorbance detector.  Each configuration of the 
HPLC system was controlled with ChromNav software from Jasco.  The chromatograms were 
analyzed with Peakfit 4.12 from Jandel Scientific Software (San Rafael, CA, USA). 
CE was performed with a P/ACE MDQ system that was equipped with a UV absorbance 
detector (Beckman Instruments, Fullerton, CA, USA).  This system was controlled with 32 
Karat 7.0 software from Beckman and used 60.2 cm × 50 μm i.d. fused silica capillaries from 
Polymicro Technologies (Phoenix, AZ, USA) with an effective length to the detector of 50 cm.  
Each new capillary was activated by rinsing it with 1.0 M sodium hydroxide for 30 min, 
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followed by a 10 min rinse with water.  The electropherograms were analyzed using Peakfit 
4.12 software. 
2.3  Preparation of AGP microcolumns 
The immobilization of AGP onto hydrazide-activated silica support was performed by 
using a modified form of a previous method [30].  The AGP was oxidized by combining 1.0 mL 
of 5.0 g L
-1
 AGP with 1.0 mL of 20 mM periodic acid, with both of these solutions being 
prepared in 0.10 M acetate buffer (pH 5.5).  This oxidation reaction was allowed to occur for 
0.5 h in the dark and at room temperature.  The oxidized AGP was washed five times with 0.10 
M potassium phosphate buffer (pH 7.0) by using a centrifugal filter.  Hydrazide-activated silica 
was prepared as described previously [31]; a 0.20 g portion of this activated support was 
combined with the purified oxidized AGP in 2.0 mL of 0.10 M potassium phosphate buffer (pH 
7.0).  This slurry was allowed to react for three days at 4
o
C with constant mixing.  The 
non-immobilized AGP was washed away from the support by using centrifugation and 0.10 M 
potassium phosphate buffer (pH 7.0).  A 40 mg portion of sodium cyanoborohydride was added 
to the support and allowed to react for 2 h to reduce the hydrazone bonds between the AGP and 
support to a more stable form [32].  An 18 mg portion of D-glucose was added to the slurry and 
allowed to react for 1 h at room temperature to cap any unreacted hydrazide groups on the 
support [33].  The final AGP support was washed three times with 0.10 M potassium phosphate 
buffer (pH 7.0), by means of centrifugation, and stored in this same buffer at 4
o
C.  The amount 
of immobilized AGP was determined in triplicate by comparing absorbance measurements made 
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at 280 nm for portions of the AGP solution (i.e., 100 μL diluted 10-fold with 0.10 M potassium 
phosphate buffer, pH 7.0) that were taken before and after the immobilization step. 
The AGP support was downward slurry-packed into 2.1 mm i.d. × 1.0 cm long stainless 
steel microcolumns at a pressure of 3000 psi (20.7 MPa).  The packing solution was 0.067 M 
potassium phosphate buffer (pH 7.4).  A control microcolumn was prepared in the same manner 
with the same type of silica but with no AGP being present during the immobilization step.  The 
microcolumns were stored in the pH 7.4 phosphate buffer at 4
o
C when not in use.  An AGP 
column that was prepared in this manner was found to be stable for more than 6 months. 
2.4  Preparation and labeling of Fab fragments and antibodies 
Fab fragments were prepared by digesting the anti-AGP antibodies with immobilized 
papain, as per the manufacturer’s instructions (see Supplemental Material for details).  The Fab 
fragments (in a solution volume of about 700 µL) were affinity-purified at room temperature by 
adding 0.13 g of AGP silica, as prepared in Section 2.3.  After allowing this mixture to react for 
5 min, the AGP support was washed three times with 1.0 mL of 0.067 M sodium phosphate (pH 
7.4).  Anti-AGP Fab fragments that were bound to this support were released by washing the 
AGP silica three times with 1.0 mL of 0.10 M phosphate buffer (pH 2.5).  The purified 
anti-AGP Fab fragments were placed into 0.067 M sodium phosphate buffer (pH 7.4) and 
concentrated to a volume of 1.0 mL by using a centrifugal filter.  The final solution was stored 
at 4
o
C or used immediately for labeling or assays. 
The anti-AGP antibodies and Fab fragments were labeled with NHS-fluorescein as 
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described previously (see Supplemental Material) [19].  The anti-AGP antibodies were reacted 
with a 24-fold mol excess of NHS-fluorescein, and the corresponding Fab fragments were reacted 
with a 28- or 280-fold mol excess of the same labeling agent.  The final preparations had a 
solution volume of ~130 µL and a concentration of ~0.9 g L-1 for the fluorescein-labeled 
anti-AGP antibodies or a concentration of ~23 mg L-1 for the fluorescein-labeled Fab fragments.  
These and the other labeled binding agents that were prepared for this study were stored at 4ºC 
and used within one week. 
Anti-AGP antibodies were also labeled, after being oxidized with periodic acid, by using 
LyCH and methods adapted from the literature (see Supplemental Material) [34].  A 200-fold 
mol excess of LyCH was used versus the oxidized antibodies, followed by the use of sodium 
cyanoborohydride to reduce the hydrazone bond between the LyCH and oxidized antibodies to a 
more stable form.  The final antibody solution was washed and concentrated by using 0.067 M 
sodium phosphate buffer (pH 7.4) and a centrifugal filter.  The final volume of the labeled 
anti-AGP antibody solution was 1.0 mL and the concentration was ~0.92 g L-1.  
The labeling ratio for the antibodies or Fab fragments was determined in triplicate through 
absorbance measurements, with the results being combined with the reported molar absorptivity 
of each label or binding agent.  These measurements were made at 280 nm to find the antibody 
or Fab content of the solution and at 494 or 428 nm, respectively, to determine the amount of 
fluorescein or LyCH label that was present. 
2.5  Conditions for one-site immunometric assay 
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The following conditions were used for the final one-site immunometric assay that was 
developed in this project.  A 1.0 μL sample of serum was dissolved in 2.5 mL of a 1.0 mg L-1 
solution of normal AGP that was prepared in 0.067 M sodium phosphate buffer (pH 7.4) (Note: 
The purpose of adding this normal AGP to the sample was to adjust the response to fall within 
the linear range of the assay when using intact labeled antibodies, as discussed later in Section 
3.6).  A 27.5 μL aliquot of this solution was mixed with 26.8 μL of 41.1 mg L-1 fluorescein 
labeled anti-AGP antibodies in 0.067 M sodium phosphate buffer (pH 7.4) and 55.7 μL of 0.067 
M sodium phosphate buffer (pH 7.4).  This mixture had final concentrations for labeled 
anti-AGP antibodies and AGP of 10.0 mg L
-1
 and 0.25 mg L
-1
, respectively, and a total volume of 
110 μL.  The original serum sample was diluted by 10,000-fold during this process (see 
Supplemental Material for issues to consider with regards to matrix effects when using less dilute 
samples).  
Standard solutions of AGP were prepared by adding 26.8 μL of 41.1 mg L-1 fluorescein 
labeled anti-AGP antibodies into various volumes of a 1.0 mg L
-1
 AGP stock solution in 0.067 M 
sodium phosphate buffer (pH 7.4).  Additional 0.067 M sodium phosphate buffer (pH 7.4) was 
added to bring the total solution volume up to 110 μL.  The AGP concentrations in these 
standards typically ranged from 0.25 to 0.55 mg L
-1
.  A concentration of 0.25 mg L
-1
 AGP was 
used as the starting point for the calibration curve to avoid the non-linear response that occurred 
at lower AGP concentrations when using intact antibodies (see Sections 3.5-3.6). 
 The one-site immunometric assay was performed on a 2.1 mm i.d. × 1.0 cm AGP 
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microcolumn by using 0.067 M sodium phosphate buffer (pH 7.4) as the application buffer.  
Sample injections were made at 0.30 mL min
-1
.  After non-retained sample components were 
allowed to wash from the microcolumn for 2 min, an elution buffer consisting of 0.10 M 
glycine-HCl (pH 2.7) was passed through the system at 0.50 mL min
-1
 for 3 min.  The 
microcolumn was then regenerated with the original application buffer at 0.30 mL min
-1
 for 3 
min.  The injection volume was 20 μL and the AGP microcolumn was maintained at 25 oC 
throughout this study.  Three replicate injections were performed for each type of sample, with 
a separate cycle of injection, elution and column regeneration being used per sample.  An 
excitation wavelength of 494 nm and an emission wavelength of 518 nm were used for detecting 
the fluorescein-labeled antibodies or labeled Fab fragments.  An excitation wavelength of 428 
nm and emission wavelength of 540 nm were used for LyCH-labeled binding agents. 
2.6  Sample preparation and conditions for capillary electrophoresis 
The sample pretreatment methods and CE analysis conditions were the same as described 
in a previous report [29].  A 65 μL portion of serum was combined and mixed with 130 μL of 
0.50 M perchloric acid, with the latter being prepared in water and used to precipitate abundant 
serum proteins while leaving AGP in the supernatant (Note: Use appropriate chemical hazard 
precautions when handling perchloric acid) [35].  This mixture was centrifuged at 6600 rpm for 
10 min at room temperature.  A 130 μL portion of the supernatant was desalted by loading the 
sample into a Zeba spin desalting column and spinning the column for 2 min at 6600 rpm and 
room temperature.  The filtrate was diluted with water to give a treated sample with total 
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volume of 5.0 mL for CE analysis.  
Each capillary used in the CE system was first cleaned by using a 5 min rinse with 1.0 M 
sodium hydroxide, followed by a 3 min rinse with water.  A coating was applied by rinsing the 
capillary for 5 min with 1.0 M hydrochloric acid and then rinsing for 5 min with a 0.2% (w/v) 
PEO solution that contained 0.10 M hydrochloric acid [36].  The capillary was rinsed for 5 min 
with a running buffer that consisted of 20 mM acetate buffer (pH 4.2) that contained 0.05% (w/v) 
PEO and 0.1% (w/v) Brij 35.  Each rinse was carried out at an applied pressure of 50 psi (0.34 
MPa), and this rinsing procedure was repeated before each CE separation.  The samples were 
electrophoretically injected by applying a potential of −5 kV to the PEO-coated capillary for 5 
min.  The applied voltage used for the separation of AGP glycoforms was -30 kV.  The 
capillary temperature was 25 
o
C and detection was performed at 200 nm [29]. 
3  Results and Discussion 
3.1  Development and characterization of AGP microcolumn 
The AGP microcolumns that were used in this study were based on the coupling of 
oxidized AGP (i.e., which contained aldehyde groups in its carbohydrate chains, as generated by 
mild oxidation with periodate) with hydrazide-activated silica.  This was carried out by using a 
modified form of a previously-reported procedure for the preparation of AGP silica (see Ref. [30] 
for details), with the addition of a step in which the hydrazone bonds formed between hydrazide 
groups on the support and aldehyde groups on AGP were reduced with cyanoborohydride to 
form a more stable bond [37,38].  It was found that final amount of AGP on the support was as 
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25.9 (± 0.1) mg AGP per gram of silica, which was roughly two-fold higher than obtained 
previously [30].  This content meant that a total of 0.40 mg (or 9.6 nmol) AGP was present in a 
2.1 mm i.d. × 1.0 cm microcolumn, based on the void volume of the column and the known 
packing density of the silica (i.e., 0.45 g silica per cm
3
).  
The amount of active AGP that was present after immobilization was also estimated.  
This was determined by performing frontal analysis [39,40] on both an AGP microcolumn and a 
control column using disopyramide as a probe that has well-characterized binding with soluble 
AGP [41].  Some typical results from these experiments are provided in the Supplemental 
Material.  It was found by this approach that the amount of active AGP in a 2.1 mm × 1.0 cm 
microcolumn, with regards to disopyramide binding, was 3.7 (± 0.3) nmol.  This meant that 39% 
of the AGP was still fully active after immobilization as a binding agent for drugs (Note: some of 
the remaining AGP would still be expected to bind to a portion of the anti-AGP antibodies in a 
polyclonal preparation even when partially inactive).  This meant the estimated binding 
capacity of such a column was at least 3-4 nmol (i.e., based on a 1:1 binding ratio of an anti-AGP 
antibody or Fab fragment with the immobilized AGP).  This amount was 920- to 2800-fold 
larger than what would be needed to fully bind 20 μL of a 10 mg L-1 solution of anti-AGP 
labeled antibodies or Fab fragments, such as used later in this study.  Alternatively, the same 
microcolumn could be used for many sample injections before the need for column elution and 
regeneration, as suggested previously [19].  Thus, this binding capacity was determined to be 
sufficient for the intended assay and this is the type of AGP microcolumn that was used in all 
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following sections of this report.  
3.2  Effect of flow rate on capture efficiency of AGP microcolumn 
Another important factor to be considered in the development of a chromatographic 
one-site immunometric assay is the flow rate at which the labeled binding agent is applied to the 
column.  This flow rate determines the extent to which this column can capture and remove the 
excess labeled binding agent from the complex of this agent with the analyte.  In this study, the 
effect of varying the injection flow rate was evaluated by injecting LyCH-labeled anti-AGP 
antibodies onto a 2.1 mm i.d. × 1.0 cm AGP microcolumn and control microcolumn at various 
flow rates.  The results were also compared to the maximum level of capture that was obtained 
for the anti-AGP antibodies before labeling, which was done to correct for the fact that not all of 
the original antibodies could bind to AGP. 
Some typical results that were obtained in these studies are shown in Figure 2.  These 
results were obtained at 0.30 mL min
-1
 and with injected samples that contained 8.0 pmol of the 
labeled antibodies (i.e., 20 µL of 60 mg L
-1
 LyCH-labeled anti-AGP antibodies).  This flow rate 
was the same as selected for use in the final one-site immunometric assay (see Section 3.6) and 
the amount of injected antibodies was six-fold larger than that used per injection in the final 
method.  This amount of labeled antibodies was 450-fold lower than expected binding capacity 
of the AGP microcolumn, as estimated in the previous section.  It can be seen that under these 
conditions that the non-retained peak for the labeled antibodies appeared within 30-60 s after 
injection.  Also, more than 70% of the labeled antibodies were captured by the AGP 
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microcolumn when compared to the total area that was measured for the same injection onto a 
control microcolumn. The remainder of the labeled antibodies, which eluted non-retained even 
from the AGP microcolumn, was approximately equal to the amount of non-labeled antibodies in 
the same type of preparation to have no binding activity for AGP (see Section 3.5).  No 
significant levels of non-specific binding by the anti-AGP antibodies to the support were noted in 
this study, as based on the observed peak areas and peak shapes that were obtained for these 
antibodies on the control microcolumn.  However, even if some non-specific binding had been 
present (i.e., decreasing the size of the non-retained antibody peak), a correction for this would 
have been made later in this study when AGP standards were used to generate a calibration curve 
for the final assay.      
Table 1 shows how the amount of bound labeled antibodies changed as the injection flow 
rate was varied from 0.10 to 0.70 mL min
-1
.  Essentially complete capture of the antibodies that 
could bind to AGP was seen when using a flow rate of 0.30 mL min
-1
 or less.  However, 
increasing the flow rate even up to 0.70 mL min
-1
 only reduced the extent of this capture by 
6-12%.  Based on these results, an injection flow rate of 0.30 mL min
-1
 was chosen for use in all 
further studies.  This flow rate made it possible to effectively capture all of the active labeled 
antibodies in the applied samples but also making it possible to measure the non-retained peak 
for these labeled binding agents within only 2 min after injection. 
3.3  Selection of labeling agent concentration 
Another factor to consider in the use of a chromatographic one-site immunometric assay 
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is the concentration or relative amount of the labeled binding agent that is to be added to a 
sample that contains the analyte.  The general process by which the labeled binding agent (Ab*) 
binds to a large analyte (A) can be described as shown in Eq. (1), 
Ab∗ + A ↔ Ab∗ ∙ A                          (1) 
where Ab*∙A is the complex formed between the labeled agent and the analyte [6].  If a large 
excess of the labeled binding agent is used versus the analyte, the concentration of Ab∗ in its 
unbound form at equilibrium ([Ab*]) will be approximately equal to the total concentration of 
this labeled agent ([Ab*]T).  When equilibrium is reached under these conditions, the fraction of 
the analyte (F) that is bound by the labeled binding agent can be estimated by using Eq. (2), 
𝐹 =
[Ab∗∙A]
[A]T
=
[Ab∗]T
Kd+[Ab
∗]T
                (2) 
where [Ab*∙A] is the concentration of the complex between Ab* and A, and [A]T is the total 
concentration of the analyte in the mixture of Ab* and A.  The term Kd is the dissociation 
equilibrium constant for the reaction shown in Eq. (1), as given by the relationship in Eq. (3). 
          Kd =
[Ab∗][A]
[Ab∗∙A]
          (3) 
Some of the labeled binding agent may lose its activity towards the analyte as a result of the 
labeling process (see Section 3.5).  To correct for this, Eq. (4) can be used in this case to 
describe the fraction of A that is bound to Ab* when only fraction f of the labeled agent is active,  
   𝐹 =
[Ab∗∙A]
[A]T
=
𝑓 [Ab∗]T
Kd+𝑓 [Ab
∗]T
               (4) 
in which the value of f is between 0.0 (for a fully inactivated binding agent) and 1.0 (for a fully 
active agent). 
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Based on Eqs. (1-4), there are two requirements placed on the concentration of the 
labeled agent for a successful one-site immunometric assay.  First, the total amount of active 
binding agent must be present in an excess when compared to the amount of the analyte that may 
be present in a sample. This relationship is represented by Eq. (5) for a system in which A can 
form a 1:1 complex with Ab* (i.e., as can occur when antibodies or smaller Fab fragments bind to 
a large analyte such as a protein). 
Requirement 1:    f [Ab*]T > [A]T          (5) 
In this study, the labeled binding agent was typically added to the pre-diluted analyte in a 20- to 
50-fold mol excess, which helped to ensure that the condition stated in Eq. (5) was met even if 
not all the labeled agent was present in an active form.   
A second requirement is that most of A will form a complex with Ab*, which maximizes 
the signal that is produced by [Ab*∙A] and results in good linearity and a low detection limit in a 
one-site immunometric assay.  Based on the relationship given earlier in Eq. (4), this situation 
occurs when the value of f [Ab*]T is larger than Kd. 
Requirement 2:    f [Ab*]T > Kd          (6) 
As is shown in Figure 3, the fraction of bound analyte (F) will be 0.50 when the active 
concentration of the labeled binding agent (f [Ab*]T) is equal to Kd.  Also, F will be greater 
than 0.90 when f [Ab*]T is at least 10-fold larger than Kd (i.e., more than 90% of the analyte is 
present in the complex Ab*∙A after incubation).  It is known that a typical polyclonal antibody 
preparation, such as that used in this study, may have dissociation equilibrium constants for the 
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target analyte that span from 10
-8
 to 10
-12
 M [8].  Therefore, for an antibody-related binding 
agent with an affinity for its target, a concentration higher than 10
-8 
M (i.e., > 1.5 mg L
-1
 for an 
intact antibody or > 0.5 mg L
-1
 for a Fab fragment) should generally be used in a one-site 
immunometric assay to ensure most of the analyte is complexed during incubation.  The actual 
concentrations of labeled binding agents that were used for method development in this study 
were at least 3.3- to 80-fold larger than this estimated requirement (i.e., even when using binding 
agents that may have a moderate Kd of only 10
-8
 M). 
3.4  Selection of incubation time 
The incubation time for the labeled binding agent with a sample also needs to be 
considered when developing a one-site immunometric assay, as this can be a limiting factor in 
the throughput of such methods [19].  As stated in the last section, the binding of a labeled 
antibody-type agent (Ab*) and the analyte (A) is usually strong (i.e., Kd < 10
-8
 M) [8]; this 
process is also essentially irreversible on a small-to-intermediate time scale (i.e., the dissociation 
rate constant, koff, is much less than the association rate constant, kon).  Under these conditions, 
the binding of Ab* with A in the reaction given earlier in Eq. (1) can be approximated by an 
irreversible second-order reaction [9] with the following rate expression.  
d[A]
dt
= −kon[A][Ab
∗]            (7) 
The expression in Eq. (7) can be simplified further by using the fact that the value of f [Ab*] 
should be much larger than [A] for an effective one-site immunometric assay, as stated earlier in 
Eq. (5).  This also means the value of f [Ab*] will be essentially constant and equal to f [Ab*]T 
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during the incubation process.  Eq. (8) shows the modified form of Eq. (7) that is obtained with 
these further assumptions, 
d[A]
dt
= −kon
′ [A]          (8) 
where kon’ is an apparent first-order association rate constant equal to the product kon f [Ab*]T.  
An estimate of the minimum incubation time that will be needed for a one-site 
immunometric assay can be obtained from Eq. (8) for selected values of kon and f [Ab*]T.  For 
instance, a typical value of kon for the interaction between antibody and a target protein is around 
10
6
 to 10
7
 M
-1
s
-1 
[9,41].  It was also determined in the previous section that f [Ab*]T should 
generally be at least 1 × 10
-8 
M, with values of 3.3-80 × 10
-8
 M actually being used in this current 
study.  By using these values with Eq. (8), it was estimated that formation of the complex 
Ab*∙A should be over 95% complete in 0.5-5.0 min.   
The incubation time needed for a one-site immunometric assay was also examined 
experimentally by preparing a mixture that contained a known amount of AGP (15 mg L
-1
) and 
labeled anti-AGP antibodies (LyCH tag, 60 mg L
-1
 Ab*).  This mixture was allowed to incubate 
for various lengths of time and injected onto an AGP microcolumn.  The amount of labeled 
antibodies that eluted non-retained was then used as a measure of how far the antibody-analyte 
reaction in Eq. (1) had proceeded to complex formation.  The results are shown in Figure 4.  It 
was again found under these conditions that over 95% of the maximum signal was reached within 
5 min of preparing this mixture (i.e., the minimum incubation time used later in this study), with 
no significant changes being seen after incubation times of 10 to 60 min.  Given the fact that at 
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least five minutes were needed to prepare a series of samples and standards for analysis, it was 
determined that the incubation step of this particular method did not contribute significantly to the 
overall analysis time.  These conditions also helped to provide a situation in which a strong 
signal due to complex formation was obtained that was consistent and stable even when longer 
incubation times may have been present (e.g., during the injection of replicates for the same 
sample mixture).  
3.5  Effect of labeling method and use of intact antibodies versus Fab fragments 
It was shown in Eqs. (4-6) and (8) that the relative activity of the binding agent can affect 
both the concentration of this agent needed to provide a strong, stable signal in a one-site 
immunometric assay and the rate at which the analyte will complex with this agent.  This 
section examined the effect on this relative activity of varying the labeling method and the use of 
intact antibodies vs Fab fragments (i.e., with two potential binding sites for the target or one site, 
respectively).  Items considered with regards to the labeling methods included the type of 
coupling chemistry that was used and the relative amount of labeling reagent that was used for 
this process.  Table 2 shows the results that were obtained when various types of labeled 
binding agents were tested for their activity by examining their extent of capture on a 2.1 mm i.d. 
× 1.0 cm AGP microcolumn (i.e., by using the approach described in Section 3.2). 
The first comparison made was in the use of intact antibodies vs Fab fragments that were 
labeled with the same type of reagent, NHS-fluorescein.  The results were compared to binding 
by the same type of anti-AGP antibodies or Fab fragments to an AGP microcolumn before the 
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labeling process.  The capture efficiency, and relative activity, of the unlabeled antibodies or Fab 
fragments was found to be 71.4 (± 3.0)% and 65.1 (± 3.8)%, respectively.  These activities were 
equivalent at the 95% confidence level, which indicated that the method used to generate the Fab 
fragments did not have a significant effect on their activity.  The reason that less than 100% 
activity was seen for the unlabeled antibodies and Fab fragments is believed to be the fact that not 
all of the antibodies in the original polyclonal preparation were able to bind to AGP and to be 
captured by the AGP microcolumn.   
Although the unlabeled antibodies and Fab fragments had essentially the same binding 
activities for AGP, this was not the case after these agents were labeled with NHS-fluorescein.  
The intact antibodies showed no significant loss in their activity when reacted with a 24:1 
mol:mol ratio with this labeling agent.  However, the Fab fragments lost between 92% and 
almost 96% of their activity when using a 28:1 or 280:1 mol:mol ratio of NHS-fluorescein for 
labeling.  This occurred even though the final amount of label that was coupled to each binding 
agent was higher for the intact antibodies (i.e., 6.3 mol mol
-1
 for the intact antibodies vs 0.8-4.2 
mol mol
-1
 for the Fab fragments).  The reason for the difference in final activity is not clear, but 
it suggests that the additional amine groups that were provided by the Fc region of the intact 
antibodies for labeling helped to protect the binding regions on these antibodies from 
inactivation by the NHS-fluorescein.   
Figure 5 illustrates the effect of this difference in activity for the labeled antibodies vs Fab 
fragments on a one-site immunometric assay.  The change in response of these calibration 
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curves (i.e., as the amount of AGP was varied) represented the signal that was due to the labeled 
antibody- or Fab-AGP complexes; the background response (i.e., as obtained when no AGP was 
added) was due to the non-retained fraction of the labeled binding agent.  Both types of labeling 
agents gave an essentially linear response at low-to-moderate AGP concentrations (correlation 
coefficients of 0.9935 and 0.9933, respectively, at n = 5 for the labeled Fab fragments and 
antibodies at 0.00-0.50 mg L
-1
 AGP); this similarity in behavior suggested that both the intact 
antibodies and Fab fragments had 1:1 binding to AGP over this concentration range.  A slight 
deviation from linearity possibly occurred at the lower end of the calibration curve for the intact 
antibodies (< 0.10 mg L
-1
 AGP, as addressed in Section 3.6), which may have been caused by 
some antibodies binding to both soluble and immobilized AGP under these conditions.  
However, the greater activity and higher level of labeling for the antibodies meant they had a 
much lower signal for their non-retained peak when no AGP was present in the sample (i.e., a 
difference of 4.2-fold in Figure 5).  The labeled intact antibodies also had a larger slope in 
Figure 5 for their change in response with AGP levels (i.e., a 2.2-fold increase over the labeled 
Fab fragments), and better precision when used in replicate measurements (see error bars in 
Figure 5).  Based on these results, labeled intact antibodies were used in all further experiments 
in this study.  An alternative would have been to use immobilized AGP to affinity-purify the 
labeled Fab fragments to increase their activity [15], which would have also increased the time 
and effort involved in reagent preparation.     
The next comparison was between the intact anti-AGP antibodies that were labeled with 
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an amine-reactive tag (i.e., NHS-fluorescein) versus a more site-selective labeling agent (i.e., 
LyCH).  The second of these agents was coupled through a hydrazide group to aldehyde groups 
that were generated in the carbohydrate chains of the antibody’s Fc region [42].  The relative 
amount used for these labeling agents was 24:1 mol:mol antibody for the NHS-fluorescein and 
200:1 mol:mol for the LyCH, based on the literature [19,34].  As is shown in Table 2, both these 
reagents and labeling conditions gave essentially the same level of activity in the final antibody 
preparation and no significant loss in activity from the unlabeled antibodies.  Labeling based on 
NHS-fluorescein was selected for use in further assay development due to the higher labeling 
ratio that was obtained with this reagent (i.e., 6.3 vs. 2.2 mol mol
-1
 antibody for LyCH), the 
greater brightness of this tag and higher signal obtained due to this label [43,44], and the ~3-fold 
lower cost of this reagent. 
3.6  Evaluation of one-site immunometric assay for AGP 
In the conditions selected for the final assay, the AGP/labeled antibody mixture contained 
10.0 mg L
-1
 (or 67 nM) of the labeled anti-AGP antibodies, an added concentration of 0.25 mg 
L
-1
 AGP, and additional AGP from the sample or standard.  The 0.25 mg L
-1
 AGP was added to 
all samples and standards to avoid the small non-linear response seen at low AGP concentrations 
in Figure 5.  As mentioned in the previous section, this non-linearity was probably due to 
binding by some antibodies to both soluble and immobilized AGP through their two available 
binding sites to this target [9].  The overall mixture was allowed to incubate for at least 5 min 
and then injected in a 20 µL volume onto a 2.1 mm i.d. × 1.0 cm AGP microcolumn at 0.30 mL 
         
26 
 
min
-1
.  The size of each non-retained peak was then measured and related to the AGP content. 
Figure 6(a) shows some typical chromatograms and a calibration curve that was obtained 
with this assay.  A signal for the non-retained peak was obtained within 30-45 s after injection, 
with the size of this peak increasing as the concentration of AGP was increased.  Complete 
elution of the non-retained peak for even high-concentration AGP samples was obtained within 2 
min.  The within-day precision of the measurements for the non-retained peaks, over the range 
of concentrations shown in Figure 6(b), ranged from ± 0.6 to 2.0% (n = 3).  The within-day 
precision of the retention times during these same injections was ± 0.4 to 0.9% (n = 3).   
This method gave a linear response at low-to-moderate AGP concentrations; for instance, 
the best-fit line in Figure 6(b) had a correlation coefficient of 0.9940 (n = 7), with an estimated 
detection limit at S/N = 3.3 of 0.026 mg L
-1
 AGP (or 630 pM).  This detection limit was 
approximately 10
4
-fold lower than the normal concentration of AGP in human serum and was 
sufficient for the detection of this protein even in highly-diluted small serum volumes, as shown 
in the next paragraph (i.e., a 10,000-fold dilution of 1 μL serum) [22,23].  The upper end of the 
linear range occurred at approximately 0.5 mg L
-1
, as shown earlier in Figure 5.  
Figure 7 shows the results that were obtained when this assay was used to measure the 
AGP concentrations in both normal commercial serum and in individual serum samples from 
several patients with SLE (i.e., a condition in which elevated AGP levels often occur).  Each of 
these measurements were made by using 1 μL portions of serum that were diluted by 10,000-fold 
in the final AGP/labeled antibody mixtures.  Some typical chromatograms that were obtained 
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with these samples are shown in Figure 7(a).  The results were again obtained in 30-45 s after 
injection, with complete elution of each non-retained peak within 2 min.   
It was possible from the areas of these peaks to determine the concentration of AGP in 
each sample.  These results are summarized in Table 3.  The measured concentrations of AGP 
in these samples ranged from 1.17 to 3.71 g L
-1
 and had precisions of ± 2.5 to 12.3% (average, ± 
7.4%).  The amount of AGP in the commercial serum sample was found to be 1.17 (± 0.11) g 
L
-1
 which was consistent with concentration expected in a normal serum [22].  The AGP 
concentrations found in the SLE serum samples were 1.5- to 3.2-fold higher than seen in the 
normal serum, as has been noted previously for patients who suffer from this disease, and 
especially when secondary infections are present [45].   
The concentrations of AGP in the same serum samples were also measured by a CE 
method that employed a neutral capillary coating and electrophoretic injection [29].  This 
second method used 65 μL of each serum sample and required precipitation of the AGP and 
desalting of the protein preparation prior to analysis [29].  Results were obtained within about 
20 min of sample injection onto the CE system, as shown in Figure 7(b).  The general trends in 
the SLE vs normal serum samples were similar in the CE method and the one-site immunometric 
assay.  In the case of the CE method, the level of change for AGP in the SLE serum spanned 
from 1.1- to 2.4-fold.  This observed change was slightly smaller than the level of increase that 
was seen with the one-site immunometric assay and may have been due to the additional 
precipitation and sample pretreatment steps that were needed in the CE technique [29]. Such 
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steps were avoided in this report due to the selective binding of AGP to the anti-AGP antibodies 
and the capture of the excess labeled antibodies by the AGP microcolumn.  
4  Conclusion 
In this study, a one-site immunometric assay using affinity microcolumns was developed 
and optimized for the analysis of AGP, which was used as a model protein biomarker.  The 
theory of chromatographic-based one-site immunometric assays was used to help design this 
method.  Factors that were considered included the binding capacity and capture efficiency of 
the affinity microcolumn; the type and concentration of the labeled binding agent; and the 
conditions used to incubate this agent with the sample.   
The final method was evaluated in terms of its response, speed, precision, and results 
versus other methods.  Conditions were identified which provided a linear response at 
low-to-moderate protein concentrations and which gave a detection limit with a 
fluorescein-based label of only 630 pM.  This limit of detection was at a level that should be 
suitable when extending this approach to a wide range of other low-to-moderate level proteins in 
serum [21].  The final method for AGP required only 1 μL of human serum for a series of 
replicate injections and had a potential sample throughput of 30 samples per hour, or 2 min per 
sample.  The affinity microcolumns that were used in this method were stable over 6 months of 
use and more than 430 injections.  In addition, the overall method gave precise results (± 
2.5-12.3%) with good correlation vs the literature and a reference method [22,29].  Future work 
may examine in more detail the accuracy, precision, stability, and utility of this method with the 
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goal of validating and further optimizing this approach for the routine clinical analysis of AGP in 
SLE or other disease states [20,22-29].  The same approach could be used to create assays for 
other protein biomarkers by changing the labeled binding agent and immobilized protein within 
the microcolumn.  Examples of potential applications include the analysis of tumor biomarkers 
and of trace proteins or modified forms of these proteins for personalized medicine [20,46]. 
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Figure legends 
 
 
 
 
 
Figure 1. General scheme for a chromatographic one-site immunometric assay, as illustrated 
for the analysis of α1-acid glycoprotein (AGP). 
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Figure 2. Non-retained peaks obtained for 20 μL injections of 60 mg L-1 LyCH-labeled 
anti-AGP antibodies (Ab*) made onto a 2.1 mm i.d. × 1.0 cm AGP microcolumn 
and a control microcolumn at 0.30 mL min
-1
.  Other conditions are given in the 
text. 
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Figure 3. Predicted fraction, F, of analyte A that will be complexed with a labeled binding 
agent (Ab*) as a function of the concentration of the labeled binding agent ([Ab*]), 
the fraction of this agent that is active (f), and the dissociation equilibrium constant 
for the binding of Ab* with A (Kd).  These plots are based on Eq. (4) and assume 
that Ab* is present in a large excess versus A. 
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Figure 4.  The effect of incubation time on the binding of labeled anti-AGP antibodies with 
AGP.  These results are for a mixture that contained 60 mg L
-1
 (400 nM) of 
LyCH-labeled anti-AGP antibodies and 15 mg L
-1
 (360 nM) AGP and that was 
allowed to incubate for various periods of time at room temperature.  Samples of 
this mixture were injected in 20 µL volumes onto a 2.1 mm i.d. × 1.0 cm AGP 
microcolumn at 0.30 mL min
-1
 to determine the response due to the non-retained 
labeled antibodies. 
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Figure 5. Response obtained in a chromatographic one-site immunometric assay for a series 
of AGP standards that were diluted by 10,000-fold and incubated with (a) 33 nM 
fluorescein-labeled anti-AGP Fab fragments or (b) 33 nM (5 mg L
-1
) 
fluorescein-labeled anti-AGP antibodies.  These mixtures were injected onto a 2.1 
mm i.d. × 1.0 cm AGP microcolumn at 0.30 mL min
-1
.  The AGP concentrations 
shown on the x-axis represent the final values for the diluted standards. Other 
conditions are given in the text.  The correlation coefficients for the best-fit lines 
shown in these plots (over all data points in black) were (a) 0.9935 and (b) 0.9933.  
The error bars represent a range of ± 1 S.D. (n = 3). 
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Figure 6. (a) Typical non-retained peaks seen for AGP standards in a one-site immunometric 
assay, after correction for the blank response that was obtained at 0.0 mg L
-1
 AGP.  
(b) Calibration curve obtained by the one-site immunometric assay, where the 
x-axis shows the final diluted concentration of AGP from the standard.  The 
experimental conditions are described in the text.  The error bars represent a range 
of ± 1 S.D. (n = 3). 
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Figure 7. (a) Chromatograms obtained in a one-site immunometric assay for AGP in normal 
serum or serum from SLE patients, and (b) electropherograms acquired in a 
CE-based assay for the same group of samples.  The chromatograms in (a) were 
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corrected for the blank response obtained with a 0.0 mg L
-1
 AGP standard.  The 
conditions used in (a) and (b) are given in the text. 
Table 1.  Extraction efficiency for LyCH-labeled anti-AGP antibodies when applied to a 2.1 
mm I.D. × 1.0 cm AGP microcolumn
a
 
Flow rate (mL min
-1
) Amount bound by AGP 
microcolumn (%) 
Amount bound vs. 
non-labeled antibodies (%)
b
 
0.10 76.7 (± 0.6) 107.4 (± 4.6) 
0.30 71.7 (± 0.7) 100.4 (± 4.4) 
0.50 70.0 (± 0.5) 98.0 (± 4.3) 
0.70 66.8 (± 0.6) 94.6 (± 4.0) 
 
a
The numbers in parentheses represent ± 1 S.D. (n = 3). 
b
These values were calculated by comparing the results for the labeled antibodies with a 
maximum capture level and activity of 71.4 (± 3.0)% for the non-labeled anti-AGP antibodies on 
the AGP microcolumn. 
Table 2.  Activity of anti-AGP antibodies or Fab fragments after using various labeling 
conditions
a
 
Label & binding agent Label used per 
binding agent 
(mol:mol) 
Final label 
ratio 
(mol:mol) 
Relative 
binding 
activity (%) 
Reduction in 
activity due to 
labeling (%)
b
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a
The numbers in parentheses represent ± 1 S.D. (n = 3).
 
b
The activity of the anti-AGP Fab fragments before labeling was 65.1 (±3.8)%, and the activity of 
the anti-AGP antibodies before labeling was 71.4 (± 3.0)%.   
c
These values were not significantly different at the 95% confidence level from those obtained 
for the unlabeled binding agents. 
Table 3.  Measured concentration of AGP in serum samples
a
 
Sample
b
 
Conc. AGP (g L
-1
) – 
One-site 
immunometric assay 
Relative conc. vs. normal 
serum - One-site 
immunometric assay 
Relative conc. vs. 
normal serum – CE 
Normal serum 1.17 (± 0.11) 1.00 1.00 
SLE serum 1 1.77 (± 0.17) 1.51 (± 0.21) 1.49 (± 0.14) 
SLE serum 2 1.77 (± 0.16) 1.51 (± 0.20) 1.21 (± 0.11) 
NHS-Fluorescein, 
anti-AGP Fab  
280:1 
28:1 
4.2:1 
0.8:1 
5.7 (± 0.9) 
3.0 (± 1.8) 
92.0 (± 1.5) 
95.8 (± 2.8) 
NHS-Fluorescein, 
anti-AGP antibodies  
24:1 6.3:1 67.0 (± 1.5) 6.2 (± 4.5)
c
 
LyCH,  
anti-AGP antibodies 
200:1 2.2:1 71.7 (± 0.7) -0.4 (± 4.4)
c
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SLE serum 3 3.71 (± 0.20) 3.18 (± 0.35) 2.44 (± 0.20) 
SLE serum 4 2.77 (± 0.07) 2.37 (± 0.24) 1.71 (± 0.28) 
SLE serum 5 2.28 (± 0.28) 1.96 (± 0.30) 1.12 (± 0.13) 
SLE serum 6 2.34 (± 0.08) 2.00 (± 0.20) 1.15 (± 0.10) 
a
The numbers in parentheses represent ± 1 S.D. (n = 3). 
b
Terms: SLE, systemic lupus erythematosus. 
         
